Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

478 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-07-2019 | Screening | News | Article

    Expansion of USPSTF lung screening criteria warranted

    This was also the case when the criteria were applied to the 791 African–American and 478 White participants who developed lung cancer, at 32.2% and 56.5%, respectively, with the ineligibility primarily due to significantly fewer smoking pack–years in the African–American than White group, at a median of 25.8 versus 48.0 pack–years.

  2. 08-03-2019 | Prostate cancer | News | Article

    Hypofractionated RT noninferior to conventional for QoL in low-risk prostate cancer

    A total of 478 men who were treated with conventional (73.8 Gy in 41 fractions over 8.2 weeks) and 484 treated with hypofractionated RT (70 Gy in 28 fractions over 5.6 weeks) reported similar changes from baseline in the vast majority of QoL outcomes at 6, 12, 24, and 60 months.

    Published in:
    JAMA Oncol 2019; doi:10.1001/jamaoncol.2018.6752
  3. 22-08-2018 | FDA | News | Article
    approvalsWatch

    FDA announces approvals for metastatic SCLC, unresectable HCC

    The agent was shown to be noninferior to sorafenib in terms of overall survival (OS) in the phase III REFLECT trial ; the median OS durations were 13.6 months for the 478 participants randomly assigned to receive lenvatinib and 12.3 months for their 476 counterparts given sorafenib.

  4. 20-06-2017 | Risk factors | News | Article
    EULAR 2017

    Reassuring findings on cancer risk in RA patients prescribed bDMARDs

    Likewise, Wadström said that based on 478 events among patients treated with TNF inhibitors as their first biologic and 169 among those treated with TNF inhibitors as their second biologic, there was no statistically significant risk difference compared with patients treated with csDMARDs.

  5. 19-06-2017 | Lenvatinib | News | Article
    ASCO 2017

    Lenvatinib equals sorafenib for unresectable HCC OS

    OS was a median of 13.6 months for the 478 lenvatinib-treated patients versus 12.3 months for the 476 sorafenib-treated patients, giving a hazard ratio (HR) of 0.92.

    Published in:
    J Clin Oncol 2017; 35 : 4001
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.